Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal

James, Jack E.; Keane, Michael

doi:10.1002/hup.881

Cited by 48 publications

(27 citation statements)

References 69 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…eyes closed, eyes open and performance of a repetitive task), and these effects were consistent with general findings and understanding from a large body of previous EEG research (Fisch, 1999). Furthermore, there is the important fact that the majority of previous studies investigating the effects of caffeine on sleep and EEG failed to control for caffeine withdrawal and withdrawal reversal (see James and Keane, 2007), whereas the findings of the present study and Keane et al (2007) were unconfounded by caffeine withdrawal and withdrawal processes.…”

Section: Discussioncontrasting

confidence: 68%

Effects of dietary caffeine on EEG, performance and mood when rested and sleep restricted

Keane

James

2008

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 68%

Effects of dietary caffeine on EEG, performance and mood when rested and sleep restricted

Keane

James

2008

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…28 Self-medicating insomnia and daytime sleepiness symptoms with substances such as caffeine and alcohol is considered a "quick relief " of symptoms for patients; however, these drugs paradoxically worsen symptoms. 29 The COP-SAT allowed for the increased detection of caffeine and alcohol consumption, and for the evaluation of its link with sleep problems.…”

Section: Discussionmentioning

confidence: 99%

Can a community pharmacy sleep assessment tool aid the identification of patients at risk of sleep disorders in the community: a pilot study

Kashyap¹,

Nissen²,

Smith³

et al. 2012

IPRP

View full text Add to dashboard Cite

Background: When experiencing sleep problems for the first time, consumers may often approach community pharmacists for advice as they are easily accessible health care professionals in the community. In Australian community pharmacies there are no specific tools available for use by pharmacists to assist with the assessment and handling of consumers with sleep enquiries. Objective: To assess the feasibility of improving the detection of sleep disorders within the community through the pilot of a newly developed Community Pharmacy Sleep Assessment Tool (COP-SAT). Method: The COP-SAT was designed to incorporate elements from a number of existing, standardized, and validated clinical screening measures. The COP-SAT was trialed in four Australian community pharmacies over a 4-week period. Key findings: A total of 241 community pharmacy consumers were assessed using the COP-SAT. A total of 74 (30.7%) were assessed as being at risk of insomnia, 26 (10.7%) were at risk of daytime sleepiness, 19 (7.9%) were at risk of obstructive sleep apnea, and 121 (50.2%) were regular snorers. A total of 116 (48.1%) participants indicated that they consume caffeine before bedtime, of which 55 (47%) had associated symptoms of sleep onset insomnia. Moreover, 85 (35%) consumed alcohol before bedtime, of which 50 (58%) experienced fragmented sleep, 50 (58%) were regular snorers, and nine (10.6%) had apnea symptoms. The COP-SAT was feasible in the community pharmacy setting. The prevalence of sleep disorders in the sampled population was high, but generally consistent with previous studies on the general population. Conclusion: A large proportion of participants reported sleep disorder symptoms, and a link was found between the consumption of alcohol and caffeine substances at bedtime and associated symptoms. While larger studies are needed to assess the clinical properties of the tool, the results of this feasibility study have demonstrated that the COP-SAT may be a practical tool for the identification of patients at risk of developing sleep disorders in the community.

show abstract

“…Of note, positive effects of caffeine are highlighted when the study design favors the reversal of short term withdrawal, which has not been consistently controlled for in many studies [18]. Some studies with low doses of caffeine (50-100 mg) suggest that most effects are due to withdrawal reversion in regular users [19,20].…”

Section: General Psychotropic Effects Of Caffeinementioning

confidence: 99%

Caffeine, Mental Health, and Psychiatric Disorders

Lara

2010

JAD

183

127

View full text Add to dashboard Cite

Abstract. Caffeine intake is so common that its pharmacological effects on the mind are undervalued. Since it is so readily available, individuals can adjust their own dose, time of administration and dose intervals of caffeine, according to the perceived benefits and side effects of each dose. This review focuses on human studies of caffeine in subjects with and without psychiatric disorders. Besides the possibility of mild drug dependence, caffeine may bring benefits that contribute to its widespread use. These benefits seem to be related to adaptation of mental energy to the context by increasing alertness, attention, and cognitive function (more evident in longer or more difficult tasks or situations of low arousal) and by elevating mood. Accordingly, moderate caffeine intake (< 6 cups/day) has been associated with less depressive symptoms, fewer cognitive failures, and lower risk of suicide. However, its putative therapeutic effects on depression and ADHD have been insufficiently studied. Conversely, in rare cases high doses of caffeine can induce psychotic and manic symptoms, and more commonly, anxiety. Patients with panic disorder and performance social anxiety disorder seem to be particularly sensitive to the anxiogenic effects of caffeine, whereas preliminary data suggests that it may be effective for some patients with obsessive compulsive disorder (OCD). The threshold for the anxiogenic effect of caffeine is influenced by a polymorphism of the A2A receptor. In summary, caffeine can be regarded as a pharmacological tool to increase energy and effortful behavior in daily activities. More populational (cross-sectional and prospective) and experimental studies are necessary to establish the role of caffeine intake in psychiatric disorders, especially its putative efficacy on depressive mood and cognitive/attentional disorders.

show abstract

Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal

Cited by 48 publications

References 69 publications

Effects of dietary caffeine on EEG, performance and mood when rested and sleep restricted

Effects of dietary caffeine on EEG, performance and mood when rested and sleep restricted

Can a community pharmacy sleep assessment tool aid the identification of patients at risk of sleep disorders in the community: a pilot study

Caffeine, Mental Health, and Psychiatric Disorders

Contact Info

Product

Resources

About